Omeros Insider Buying Signals Confidence: Borges Buys Shares Amid 10(b)(5)(1) Plan

Insider Activity Highlights Omeros’ Momentum

On August 13 2026, David J. Borges, Vice‑President of Finance and Chief Accounting Officer at Omeros Corp., executed a series of transactions that, while modest in dollar value, reflect a broader pattern of executive confidence in the company’s strategic trajectory. Under a 10(b)(5)(1) trading plan—a legally sanctioned framework that allows insiders to purchase shares in a predetermined, orderly manner—Borges added 5,000 shares at $3.93 per share. This purchase is offset by the sale of 5,000 shares that had vested from an earlier option grant at $16.95, as well as the exercise of 5,000 option shares that vested over a 48‑month period. The net result is a slight increase in Borges’s overall holdings, but the significance lies in the sustained optimism that senior leadership holds for Omeros’s future.

Insider Buying as a Signal for Investors

The transaction by Borges is part of a wider wave of insider buying observed across Omeros’ leadership team. CEO Gregory Demopulos and other executives have actively exercised sizeable option grants, a clear indication that they are betting on the same value creation that shareholders seek. For investors, this alignment of incentives is a positive barometer: executives are not merely passive stakeholders; they are investing their own capital in the company’s prospects. Although Borges’s purchase represents a small fraction of the firm’s $1.24 billion market capitalisation, it is strategically significant. The disciplined nature of the 10(b)(5)(1) plan underscores that the purchase is not opportunistic but part of a long‑term investment strategy.

Corporate Governance and Strategic Positioning

Omeros is positioned within a high‑growth specialty‑pharma segment that spans orthopedics, rheumatology, and cardiovascular medicine. Recent Rule 144 and S‑8 filings have opened additional shares for employees, signalling a deliberate move to broaden equity distribution and fund future research and expansion. The board’s expansion to nine directors and the appointment of seasoned investor Joseph Schocken further strengthen corporate governance and strategic oversight. Together, these corporate actions reinforce a narrative of confidence in Omeros’s scientific assets and a commitment to scaling operations and enhancing shareholder returns.

Consistent Commitment of David J. Borges

A review of Borges’s historical transaction pattern shows a disciplined approach to equity participation. Over the first half of 2026, he maintained holdings between 30,000 and 105,000 shares, balancing liquidity needs with long‑term investment. His recent 10(b)(5)(1) plan trade demonstrates adherence to regulatory safeguards while maintaining an active stake. This consistency underlines his belief that Omeros will continue to deliver on its therapeutic targets and that the company’s growth trajectory remains sound.

Bottom Line for Financial Professionals

For analysts and portfolio managers, Borges’s insider activity—coupled with the broader leadership’s option exercising—provides a useful barometer of internal confidence. While the trades themselves are small in dollar terms, they are part of a larger narrative of strategic equity distribution, board strengthening, and pipeline optimism. Monitoring insider buying can help assess whether Omeros is positioned for sustained growth and inform timing decisions for investment participation, especially in a company that actively aligns executive and shareholder interests.